Oncovisions's Preclinical PET Imaging Business moves to Bruker

Bruker is to acquire the preclinical imaging business of Oncovision, a leading provider of medical imaging devices used for the diagnosis of cancer. For the past five years, Bruker and Oncovision have held an exclusive marketing agreement for Albira™ PET/SPECT/CT systems, developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology and collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system.

Dr. Wulf I. Jung, President of Bruker’s Preclinical Imaging Division, stated:  “With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations.”
 

Ignasi Vivas, CEO of Oncovision, commented: “Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of Bruker's molecular imaging technologies and fulfill the growing demand from translational scientists.”
 

As part of the agreement, Oncovision will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging. A German-Spanish team of the law firm CMS acted as legal adviser to Bruker.